140
Participants
Start Date
June 27, 2024
Primary Completion Date
June 27, 2025
Study Completion Date
June 20, 2027
UC-MSCs
3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
Placebo(solution without UC-MSCs)
3 doses of placebo intravenously at day 1, day 8, day 15.
RECRUITING
Shanghai Changzheng Hospital, Shanghai
NOT_YET_RECRUITING
The First Hospital of Lanzhou University, Lanzhou
NOT_YET_RECRUITING
Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou
RECRUITING
Hainan hospital of Chinese PLA General Hospital, Sanya
NOT_YET_RECRUITING
Jin Yin-tan Hospital, Wuhan
NOT_YET_RECRUITING
Xinjiang Kashi Area Number 1 Hospital, Kashgar
RECRUITING
Beijing 302 Hospital, Beijing
Chinese PLA General Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
LanZhou University
OTHER
Jin Yin-tan Hospital
UNKNOWN
Hainan Hospital of Chinese PLA General Hospital
UNKNOWN
Vcanbio Cell and Gene Engineering Corp., Ltd.
INDUSTRY
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Xinjiang Kashi Area Number 1 Hospital
UNKNOWN
Beijing 302 Hospital
OTHER